NeuroBell develops novel medical device solutions for neonatal care. The company provides portable EEG monitoring systems designed for use at the Neonatal Intensive Care Unit (NICU) bedside. This technology offers automated seizure detection to improve timely diagnosis and treatment of newborn brain injuries.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Newborn seizures often lack physical signs, requiring specialized neurological monitoring equipment and expertise for detection. Delays in diagnosis and treatment can lead to further brain injury in neonates. Current EEG monitoring solutions are often not readily available at the bedside, leading to critical delays.
Solution
NeuroBell is developing a portable EEG monitoring device designed to provide real-time, automated seizure detection in neonates. This point-of-care solution aims to address the challenges of delayed diagnosis by enabling immediate neurological assessment at the bedside. The device is intended to be easily accessible and user-friendly, facilitating timely intervention and potentially improving outcomes for newborns at risk of brain injury. By providing continuous monitoring and automated detection, NeuroBell seeks to reduce the reliance on specialized expertise and equipment, making neonatal EEG monitoring more accessible in various clinical settings.
Target Audience
The primary target audience includes neonatal intensive care units (NICUs), hospitals, and medical professionals involved in newborn care.
Features
- Portable EEG monitoring device for neonates.
- Real-time, automated seizure detection.
- Designed for bedside use.